Breast Neoplasms

Oncology
73
Pipeline Programs
28
Companies
50
Clinical Trials
4 recruiting
6
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
13
4
36
0
10
10
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
850%
ADC
531%
Monoclonal Antibody
213%
Vaccine
16%
+ 60 programs with unclassified modality

On Market (6)

Approved therapies currently available

Pfizer
AROMASINApproved
exemestane
Pfizer
Aromatase Inhibitor [EPC]oral1999
U
EXEMESTANEApproved
exemestane
Unknown Company
Aromatase Inhibitor [EPC]oral2017
E
HALAVENApproved
eribulin mesylate
Eisai
intravenous2010
Novartis
KISQALI FEMARA CO-PACK (COPACKAGED)Approved
letrozole and ribociclib
Novartis
oral2017
Novartis
TYKERBApproved
lapatinib
Novartis
oral2007
Eli Lilly and Company
VERZENIOApproved
abemaciclib
Eli Lilly and Company
Kinase Inhibitor [EPC]oral2017

Competitive Landscape

26 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
12 programs
1
5
2
1
exemestanePhase 41 trial
PD-0332991Phase 34 trials
exemestanePhase 35 trials
CI-1033Phase 21 trial
CP-724,714Phase 21 trial
+7 more programs
Active Trials
NCT01239745Terminated46Est. Oct 2011
NCT01176916Completed564Est. Nov 2018
NCT01155063Terminated89Est. Sep 2011
+24 more trials
E
EisaiChina - Liaoning
8 programs
2
1
3
2
Eribulin MesylatePhase 41 trial
Eribulin mesylatePhase 41 trial
E7070Phase 21 trial
E7389Phase 21 trial
EribulinPhase 21 trial
+3 more programs
Active Trials
NCT04572295Active Not Recruiting51Est. Mar 2027
NCT04568902Completed33Est. Oct 2025
NCT03250676Completed151Est. Oct 2023
+5 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
5 programs
1
2
2
1
AbemaciclibPhase 3Small Molecule1 trial
LY353381Phase 31 trial
GemcitabinePhase 21 trial
pemetrexedPhase 21 trial
LY3484356Phase 11 trial
Active Trials
NCT05509790Active Not Recruiting17Est. Dec 2026
NCT00191672Completed120Est. Nov 2006
NCT00034489Completed
+2 more trials
Novartis
NovartisBASEL, Switzerland
4 programs
1
3
1
TYKERB(Lapatinib)Phase 2Small Molecule5 trials
KISQALI FEMARA CO-PACK (COPACKAGED)(Letrozole)Phase 2Small Molecule5 trials
epothilone bPhase 21 trial
[68Ga]Ga-DWJ155Phase 11 trial
Active Trials
NCT07117214Not Yet Recruiting36Est. Jan 2027
NCT02294786Terminated62Est. Oct 2017
NCT02073487Completed32Est. Jan 2019
+9 more trials
Providence Therapeutics
1 program
1
Botulinum Toxin-APhase 41 trial
Active Trials
NCT01427400UnknownEst. Dec 2017
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
14 programs
4
9
1
BIBW 2992Phase 31 trial
Afatinib once dailyPhase 21 trial
BIBW 2992Phase 21 trial
BIBW 2992Phase 21 trial
BIBW 2992Phase 21 trial
+9 more programs
Active Trials
NCT01649271Completed13Est. Jun 2016
NCT00950742Completed18Est. Oct 2013
NCT02254031Terminated8
+11 more trials
DS
Daiichi SankyoChina - Shanghai
3 programs
1
2
Patritumab deruxtecanPhase 3ADC1 trial
Trastuzumab DeruxtecanPhase 3ADC1 trial
Patritumab deruxtecanPhase 1/2ADC1 trial
Active Trials
NCT06686394Recruiting81Est. Apr 2030
NCT07060807Recruiting1,000Est. Jul 2033
NCT05113251Active Not Recruiting927Est. Apr 2027
CP
Chugai PharmaJapan - Tokyo
2 programs
1
1
FEC-DocGemzar adjuvant chemotherapyPhase 3
CALPhase 11 trial
Active Trials
NCT00051779Completed
M&
Merck & Co.RAHWAY, NJ
2 programs
1
1
Sacituzumab tirumotecanPhase 31 trial
SCH 727965Phase 21 trial
Active Trials
NCT00732810Completed97Est. Jun 2011
NCT06312176Recruiting1,200Est. Apr 2031
Lantern Pharma
Lantern PharmaDALLAS, TX
1 program
1
BNP7787Phase 31 trial
Active Trials
NCT00039780Completed764Est. Sep 2014
Bayer
BayerLEVERKUSEN, Germany
4 programs
3
BAY59-8862Phase 21 trial
Radium-223 dichloridePhase 21 trial
SorafenibPhase 2Small Molecule1 trial
ClodronateN/A1 trial
Active Trials
NCT01198457Completed147Est. Jun 2010
NCT00044525Completed82Est. Feb 2004
NCT02258464Terminated99Est. Aug 2019
+1 more trials
Amgen
AmgenTHOUSAND OAKS, CA
3 programs
2
AMG 706 placeboPhase 21 trial
Denosumab 120 mgPhase 21 trial
Health Economy RegisterN/A1 trial
Active Trials
NCT04386629Completed219Est. Dec 2020
NCT00356681Terminated282Est. Aug 2012
NCT03532087Withdrawn0Est. Jun 2023
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
3 programs
1
1
ZD1839 in combination with docetaxelPhase 21 trial
OlaparibPhase 1/21 trial
Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST CancerN/A1 trial
Active Trials
NCT07070128Recruiting800Est. Aug 2026
NCT03594396Active Not Recruiting54Est. Dec 2025
NCT00052169Completed33Est. Sep 2006
Sanofi
SanofiPARIS, France
2 programs
2
Docetaxel with CytoxanPhase 21 trial
larotaxelPhase 21 trial
Active Trials
NCT00832338Terminated23Est. Oct 2015
NCT00386685Completed51Est. Jan 2011
Genentech
GenentechCA - Oceanside
1 program
1
Allogeneic GM-CSF-secreting breast cancer vaccinePhase 2Vaccine1 trial
Active Trials
NCT00399529Completed22Est. Feb 2010
Ipsen
IpsenChina - Tianjin
1 program
1
IrosustatPhase 2Small Molecule1 trial
Active Trials
NCT01662726Terminated13Est. Dec 2014
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
1
LapatinibPhase 2Small Molecule
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
Perjeta Injectable ProductPhase 21 trial
Active Trials
NCT03272477Completed257Est. Mar 2024
Bristol Myers Squibb
1 program
1
VinfluninePhase 25 trials
Active Trials
NCT00534807Withdrawn0Est. Nov 2008
NCT00545766Completed41Est. Jan 2009
NCT00359476Terminated55Est. Nov 2007
+2 more trials
Stemline Therapeutics
1 program
1
ElacestrantPhase 1/21 trial
Active Trials
NCT05386108Recruiting73Est. Dec 2026
Cytokinetics
CytokineticsSOUTH SAN FRANCISCO, CA
1 program
1
IspinesibPhase 11 trial
Active Trials
NCT00607841Terminated16Est. Nov 2009
Achieve Life Sciences
1 program
1
SN2310 Injectable EmulsionPhase 11 trial
Active Trials
NCT00385177CompletedEst. May 2009
Arvinas
ArvinasCT - New Haven
1 program
1
vepdegestrantPhase 11 trial
Active Trials
NCT05463952Active Not RecruitingEst. Mar 2025
Genomics
GenomicsUK - Oxford
1 program
ARNA BreastN/A1 trial
Active Trials
NCT04890340Unknown500Est. Dec 2021
Alliance Pharmaceuticals
1 program
Post-Treatment Surveillance in Breast Cancer: Bringing CER to the AllianceN/A1 trial
Active Trials
NCT02171078Completed34,359Est. Dec 2017
HELP Therapeutics
HELP TherapeuticsChina - Nanjing
1 program
Supportive-expressive group therapyN/A1 trial
Active Trials
NCT02934815UnknownEst. Jan 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
NovartisLetrozole
EisaiEribulin Mesylate
EisaiEribulin mesylate
Providence TherapeuticsBotulinum Toxin-A
PfizerAromasin
NovartisLetrozole
NovartisLetrozole
Pfizerexemestane
NovartisLetrozole
NovartisLetrozole
NovartisLetrozole
NovartisLetrozole
NovartisLetrozole
Pfizerexemestane
Daiichi SankyoPatritumab deruxtecan

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 66,565 patients across 50 trials

NCT05161195NovartisLetrozole

Roll-over Study to Allow Continued Access to Ribociclib

Start: Jul 2022Est. completion: Aug 2030134 patients
Phase 4Active Not Recruiting
NCT03583944EisaiEribulin Mesylate

A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer

Start: Mar 2018Est. completion: Jun 2019200 patients
Phase 4Completed
NCT01961544EisaiEribulin mesylate

Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer

Start: Jun 2013Est. completion: Jul 2015101 patients
Phase 4Completed
NCT01427400Providence TherapeuticsBotulinum Toxin-A

The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction

Start: Oct 2011Est. completion: Dec 2017
Phase 4Unknown
NCT01176916PfizerAromasin

Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China

Start: Feb 2011Est. completion: Nov 2018564 patients
Phase 4Completed
NCT01908556NovartisLetrozole

Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace)

Start: Feb 20093,545 patients
Phase 4Unknown
NCT00688909NovartisLetrozole

Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer

Start: Mar 2008Est. completion: Jun 2009261 patients
Phase 4Completed
NCT00649090Pfizerexemestane

A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer

Start: Mar 2005Est. completion: Apr 20071,549 patients
Phase 4Completed
NCT00171847NovartisLetrozole

Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer

Start: Mar 200393 patients
Phase 4Terminated
NCT00237133NovartisLetrozole

Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women

Start: Mar 2003Est. completion: Jan 2009112 patients
Phase 4Completed
NCT00237224NovartisLetrozole

Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole

Start: Feb 200340 patients
Phase 4Completed
NCT00241046NovartisLetrozole

Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment

Start: Apr 200213 patients
Phase 4Terminated
NCT00014638NovartisLetrozole

Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

Start: Jan 2001Est. completion: Mar 2002
Phase 4Completed
NCT00034125Eli Lilly and CompanyLY353381

Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

Phase 3Completed
NCT07062965Pfizerexemestane

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Start: Aug 2025Est. completion: Nov 2030400 patients
Phase 3Recruiting
NCT07060807Daiichi SankyoPatritumab deruxtecan

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Start: Jul 2025Est. completion: Jul 20331,000 patients
Phase 3Recruiting
NCT06312176Merck & Co.Sacituzumab tirumotecan

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Start: Apr 2024Est. completion: Apr 20311,200 patients
Phase 3Recruiting
NCT05827081NovartisLetrozole

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Start: Feb 2024Est. completion: Sep 20301,400 patients
Phase 3Recruiting
NCT05113251Daiichi SankyoTrastuzumab Deruxtecan

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Start: Oct 2021Est. completion: Apr 2027927 patients
Phase 3Active Not Recruiting
NCT03474107Pfizerdocetaxel

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Start: Jun 2018Est. completion: Nov 2025608 patients
Phase 3Completed
NCT03050398NovartisLetrozole

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Start: Jun 2017Est. completion: Mar 20198 patients
Phase 3Terminated
NCT02941926NovartisLetrozole

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

Start: Nov 2016Est. completion: Nov 20223,246 patients
Phase 3Completed
NCT03096847NovartisLetrozole

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Start: Oct 2016Est. completion: Feb 2020502 patients
Phase 3Completed
NCT02107703Eli Lilly and CompanyAbemaciclib

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

Start: Jul 2014Est. completion: Dec 2027669 patients
Phase 3Active Not Recruiting
NCT01958021NovartisLetrozole

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

Start: Dec 2013Est. completion: Mar 2023668 patients
Phase 3Completed
NCT01740427PfizerPD-0332991

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

Start: Feb 2013Est. completion: Nov 2023666 patients
Phase 3Completed
NCT01638247Pfizerexemestane

Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients

Start: Aug 2012Est. completion: May 201856 patients
Phase 3Completed
NCT01160211NovartisLapatinib

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Start: May 2011Est. completion: Jun 2022369 patients
Phase 3Completed
NCT01125566Boehringer IngelheimBIBW 2992

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Start: Jun 2010Est. completion: Jul 2018508 patients
Phase 3Completed
NCT01104571NovartisLapatinib

Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer

Start: Apr 2010Est. completion: Sep 2025257 patients
Phase 3Unknown
NCT00968968NovartisLapatinib

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Start: Jan 2010Est. completion: Mar 201837 patients
Phase 3Terminated
NCT00863655NovartisLetrozole

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Start: Jun 2009Est. completion: Dec 2014724 patients
Phase 3Completed
NCT00908531NovartisLetrozole

Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer

Start: May 2009Est. completion: Dec 2013123 patients
Phase 3Terminated
NCT00820222NovartisLapatinib

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

Start: Apr 2009Est. completion: Mar 2018540 patients
Phase 3Completed
NCT00667251NovartisLapatinib

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Start: Oct 2008Est. completion: Jul 2022652 patients
Phase 3Completed
NCT00680901NovartisLapatinib

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Start: Jun 2008Est. completion: Oct 2024545 patients
Phase 3Completed
NCT00490139NovartisLapatinib

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Start: May 2007Est. completion: Jul 20218,381 patients
Phase 3Completed
NCT00382070NovartisLetrozole

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

Start: Aug 2006Est. completion: Apr 20253,966 patients
Phase 3Active Not Recruiting
NCT00332852NovartisLetrozole

Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

Start: Mar 2006655 patients
Phase 3Completed
NCT00330317NovartisLetrozole

Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer

Start: Feb 2006Est. completion: Nov 2010300 patients
Phase 3Completed
NCT00281658NovartisLapatinib

Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

Start: Jan 2006Est. completion: Nov 2021444 patients
Phase 3Completed
NCT00248170NovartisLetrozole

Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer

Start: Dec 2005Est. completion: Sep 20144,172 patients
Phase 3Completed
NCT00329940NovartisLetrozole

Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

Start: Nov 2005200 patients
Phase 3Completed
NCT00143390Pfizerexemestane

Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer

Start: Apr 2005Est. completion: Dec 2010298 patients
Phase 3Completed
NCT00073528NovartisLapatinib

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Start: Dec 2003Est. completion: Mar 20181,286 patients
Phase 3Completed
NCT00279448Pfizerexemestane

Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer

Start: Jan 2002Est. completion: Jun 20099,779 patients
Phase 3Completed
NCT01237327PfizerAromasin

Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer

Start: Nov 2001Est. completion: Dec 200984 patients
Phase 3Completed
NCT00039780Lantern PharmaBNP7787

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

Start: Sep 2001Est. completion: Sep 2014764 patients
Phase 3Completed
NCT00036270PfizerAromasin

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

Start: Aug 2001Est. completion: Feb 20119,779 patients
Phase 3Completed
NCT00038467Pfizerexemestane

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

Start: Feb 1998Est. completion: Mar 20134,740 patients
Phase 3Completed

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
1h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
3h ago

Executive Director, I.T.- Head of Security Architecture, Engineering, and Delivery

Gilead Sciences
United States - California - Foster City
17h ago
$281K - $364K/yr

Sr Research Associate, Analytical Operations

Gilead Sciences
United States - California - Oceanside
17h ago
$86K - $112K/yr

Associate Director, Insights & Analytics Platform Technology Lead

Gilead Sciences
United States - California - Foster City
17h ago
$196K - $253K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

10 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 66,565 patients
28 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)